Dawson James Starts Anavex Life Sciences (AVXL) at Buy

Dawson James analyst Jason Kolbert initiates coverage on Anavex Life Sciences (NASDAQ: AVXL) with a Buy rating and a price target of $16.00.

The analyst comments "The development of Alzheimer's has been linked to different mechanisms which may trigger negative cascades. Research advances are emerging around what happens when cells undergo stress. Why do some survive, and others degenerate? One answer may relate to individual cell survival mechanisms which in-part may be related to the role of the Sigma-1 Receptor, which is activated (an agonist) by ANAVEX2-73. It is believed that Sigma 1 can help to protect a cell from the accumulation of misfolded proteins, acting to chaperone them out of the cell. As a result, cell metabolism (oxidative stress and mitochondrial dysfunction) are kept in balance. The implications here can have an impact across a wide range of neurodegenerative diseases from Alzheimer's to Parkinson's and niche orphan diseases such as Rett's syndrome, which may represent a "fast path" to establish proof of concept, around Sigma 1 agonism."

For an analyst ratings summary and ratings history on Anavex Life Sciences click here. For more ratings news on Anavex Life Sciences click here.

Shares of Anavex Life Sciences closed at $2.52 yesterday.

You May Also Be Interested In

• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
• Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'